Cargando…

Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2

Multiple outbreaks of epidemic and pandemic viral diseases have occurred in the last 20 years, including those caused by Ebola virus, Zika virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence or re-emergence of such diseases has revealed the deficiency in our pipeli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tonk, Miray, Růžek, Daniel, Vilcinskas, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156787/ https://www.ncbi.nlm.nih.gov/pubmed/34069206 http://dx.doi.org/10.3390/v13050912

Ejemplares similares

Insect antimicrobial peptides: potential tools for the prevention of skin cancer
por: Tonk, Miray, et al.
Publicado: (2016)

Bioactivity of Natural and Engineered Antimicrobial Peptides from Venom of the Scorpions Urodacus yaschenkoi and U. manicatus
por: Luna-Ramirez, Karen, et al.
Publicado: (2017)

Synergistic antiviral effects against SARS-CoV-2 by plant-based molecules
por: Prasad, Ashish, et al.
Publicado: (2020)

Potent Activity of Hybrid Arthropod Antimicrobial Peptides Linked by Glycine Spacers
por: Tonk, Miray, et al.
Publicado: (2021)

Anthelminthic Activity of Assassin Bug Venom against the Blood Fluke Schistosoma mansoni
por: Tonk, Miray, et al.
Publicado: (2020)

Antiviral Activity of Vacuolar ATPase Blocker Diphyllin against SARS-CoV-2
por: Stefanik, Michal, et al.
Publicado: (2021)

Potential Applications of Plant Biotechnology against SARS-CoV-2
por: Capell, Teresa, et al.
Publicado: (2020)

Insect Models in Nutrition Research
por: Tonk-Rügen, Miray, et al.
Publicado: (2022)

The importance of naturally attenuated SARS‐CoV‐2in the fight against COVID‐19
por: Armengaud, Jean, et al.
Publicado: (2020)

The evidence remains clear: SARS-CoV-2 emerged via the wildlife trade
por: Garry, Robert F.
Publicado: (2022)

Potential antiviral peptides against the nucleoprotein of SARS-CoV-2
por: Mahdi, Iktedar, et al.
Publicado: (2022)

T Cells: Warriors of SARS-CoV-2 Infection
por: de Candia, Paola, et al.
Publicado: (2021)

The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2
por: Bauer, Lisa, et al.
Publicado: (2022)

Understanding Laboratory Testing for SARS-CoV-2
por: Cheema, Ritu, et al.
Publicado: (2021)

The insect antimicrobial peptide cecropin A disrupts uropathogenic Escherichia coli biofilms
por: Kalsy, Miriam, et al.
Publicado: (2020)

Rapid deployment of SARS-CoV-2 testing: The CLIAHUB
por: Crawford, Emily D., et al.
Publicado: (2020)

Compelling evidence of a novel multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 infection
por: Long, Sarah S.
Publicado: (2020)

Nano-targeting lessons from the SARS-CoV-2
por: Ribeiro, I.R.S., et al.
Publicado: (2021)

Is Omicron the last SARS-CoV-2 Variant of Concern?
por: Rahimi, Farid, et al.
Publicado: (2022)

Immune Evasion of SARS-CoV-2 Omicron Subvariants
por: Ke, Hanzhong, et al.
Publicado: (2022)

A Compelling Case of Autoimmune Hemolytic Anemia and Its Potential Association With SARS-CoV-2
por: Silva, José Miguel, et al.
Publicado: (2023)

In silico evidence of beauvericin antiviral activity against SARS-CoV-2
por: Al Khoury, Charbel, et al.
Publicado: (2022)

SARS-CoV-2–A Tough Opponent for the Immune System
por: Nasab, Mahsa Golshani, et al.
Publicado: (2020)

Virus Eradication and Synthetic Biology: Changes with SARS-CoV-2?
por: Tournier, Jean-Nicolas, et al.
Publicado: (2021)

Are Older People Really More Susceptible to SARS-CoV-2?
por: Zhang, Shuo, et al.
Publicado: (2022)

Heme, Heme Oxygenase-1, Statins, and SARS-CoV-2
por: Stevenson, David K., et al.
Publicado: (2023)

Spying on SARS-CoV-2 with Fluorescent Tags and Protease Reporters
por: To, Tsz-Leung, et al.
Publicado: (2023)

SARS-CoV-2 another kind of liver aggressor, how does it do that?
por: Lozano-Sepulveda, Sonia A., et al.
Publicado: (2020)

The paradigm of immune escape by SARS-CoV-2 variants and strategies for repositioning subverted mAbs against escaped VOCs
por: Shah, Masaud, et al.
Publicado: (2022)

Compelling Evidence Suggesting the Codon Usage of SARS-CoV-2 Adapts to Human After the Split From RaTG13
por: Zhang, Yanping, et al.
Publicado: (2021)

Can We Protect Those We Care for in A Pandemic? - Prevalence of Neutralizing Antibodies against SARS-CoV-2 in Nursing Homes
por: Willschke, Harald, et al.
Publicado: (2021)

Antiviral peptides against SARS-CoV-2: therapeutic targets, mechanistic antiviral activity, and efficient delivery
por: Essa, Raahilah Zahir, et al.
Publicado: (2022)

SARS‐CoV‐2, bacterial co‐infections, and AMR: the deadly trio in COVID‐19?
por: Bengoechea, Jose A, et al.
Publicado: (2020)

SARS-CoV-2 and the next generations: which impact on reproductive tissues?
por: Zupin, Luisa, et al.
Publicado: (2020)

SARS-CoV-2: Cross-scale Insights from Ecology and Evolution
por: Snedden, Celine E., et al.
Publicado: (2021)

Why Does SARS-CoV-2 Infection Induce Autoantibody Production?
por: Macela, Ales, et al.
Publicado: (2021)

The gut microbiome as a biomarker of differential susceptibility to SARS-CoV-2
por: Sarkar, Amar, et al.
Publicado: (2021)

The Safety of Anti-SARS-CoV-2 Vaccines: Vigilance Is Still Required
por: Goldman, Michel
Publicado: (2022)

Targeting SARS-CoV-2 papain-like protease in the postvaccine era
por: Ton, Anh-Tien, et al.
Publicado: (2022)

Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines
por: Fraser, Rupsha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qddo3f3gua8tpcj83sc7aptk2k